BACKGROUND: γδT cells are effector cells that eliminate cancer and virus-infected cells. Chimpanzees are an endangered species that can naturally and experimentally be infected with SIV and HIV, respectively, but no information about the functionality of γδT cells during chronic lentiviral infection is currently available. METHODS: Healthy and HIV-infected chimpanzee γδT cells were characterized by flow cytometry. γδT subsets were studied after stimulation with T-cell activators, and the release of cytokines was analyzed by Luminex assay. RESULTS: γδT-cell subsets, Vδ1 and Vδ2Vγ9, showed different patterns in the expression of CD4, CD195, CD159a, and CD159c. Stimulation of γδT cells resulted in increased levels of CD4 and HLA-DR, which is more pronounced in Vδ1 T cells. Distinct cytokine patterns were found between healthy and HIV-infected chimpanzees. CONCLUSIONS: Analyses of major chimpanzee γδT subsets show similarities to human γδT cells and suggest different functionality and roles in their immune response against HIV infection.
BACKGROUND: γδT cells are effector cells that eliminate cancer and virus-infected cells. Chimpanzees are an endangered species that can naturally and experimentally be infected with SIV and HIV, respectively, but no information about the functionality of γδT cells during chronic lentiviral infection is currently available. METHODS: Healthy and HIV-infectedchimpanzee γδT cells were characterized by flow cytometry. γδT subsets were studied after stimulation with T-cell activators, and the release of cytokines was analyzed by Luminex assay. RESULTS: γδT-cell subsets, Vδ1 and Vδ2Vγ9, showed different patterns in the expression of CD4, CD195, CD159a, and CD159c. Stimulation of γδT cells resulted in increased levels of CD4 and HLA-DR, which is more pronounced in Vδ1 T cells. Distinct cytokine patterns were found between healthy and HIV-infectedchimpanzees. CONCLUSIONS: Analyses of major chimpanzee γδT subsets show similarities to human γδT cells and suggest different functionality and roles in their immune response against HIV infection.
Authors: P De Paoli; D Gennari; P Martelli; G Basaglia; M Crovatto; S Battistin; G Santini Journal: Clin Exp Immunol Date: 1991-02 Impact factor: 4.330
Authors: J Borst; A Wicherink; J J Van Dongen; E De Vries; W M Comans-Bitter; F Wassenaar; P Van Den Elsen Journal: Eur J Immunol Date: 1989-09 Impact factor: 5.532
Authors: V Groh; S Porcelli; M Fabbi; L L Lanier; L J Picker; T Anderson; R A Warnke; A K Bhan; J L Strominger; M B Brenner Journal: J Exp Med Date: 1989-04-01 Impact factor: 14.307
Authors: C M Parker; V Groh; H Band; S A Porcelli; C Morita; M Fabbi; D Glass; J L Strominger; M B Brenner Journal: J Exp Med Date: 1990-05-01 Impact factor: 14.307
Authors: Sharilyn Almodovar; Jessica Swanson; Luis D Giavedoni; Sreetharan Kanthaswamy; Carlin S Long; Norbert F Voelkel; Michael G Edwards; Joy M Folkvord; Elizabeth Connick; Susan V Westmoreland; Paul A Luciw; Sonia C Flores Journal: Viral Immunol Date: 2017-12-19 Impact factor: 2.257
Authors: Natasa Strbo; Maria L Alcaide; Laura Romero; Hector Bolivar; Deborah Jones; Eckhard R Podack; Margaret A Fischl Journal: Am J Reprod Immunol Date: 2015-12-15 Impact factor: 3.886
Authors: Edward J D Greenwood; Fabian Schmidt; Ivanela Kondova; Henk Niphuis; Vida L Hodara; Leah Clissold; Kirsten McLay; Bernadette Guerra; Sharon Redrobe; Luis D Giavedoni; Robert E Lanford; Krishna K Murthy; François Rouet; Jonathan L Heeney Journal: PLoS Pathog Date: 2015-09-11 Impact factor: 6.823